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Supplemental Figures 
 
Figure S1. Binding of BODIPY™ FL ATP-γ-S to WT p97 (A) and CB-5083 resistant mutants (B, C), in 
the presence or absence of CB-5083. 
 
Figure S2. cDNA sequencing results of WT and D649A/T688A p97. 
 
Figure S3. Fold resistance of mutant p97 D649A/T688A toward p97 inhibitors, as compared to WT 
p97. 
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Figure S4. Distance between NMS-873 or UPCDC-30245 binding site and T688. 
 
Figure S5. Thermal shift assay (TSA) of WT p97 and p97 mutants in the presence of different 
concentrations of CB-5083. 
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Figure S6. Western blot assay carried out to determine the change in biomarkers caused by p97 
inhibition. 
 
Figure S7. LC-MS/MS standard curves of (A) NMS-873 and (B) UPCDC-30245. 
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Supplemental Tables 
Table S1. Plasmids used in this study. 
Plasmid 
Number Plasmid name Vector 
Source and 
Reference 
TCB-197 Human p97 pET15_T pET15b_TEV linker Chou, 2014 [1] 
TCB-494 Human E470D p97 pET15_T pET15b_TEV linker Bastola, 2017 [2] 
TCB-484 Human E470K p97 pET15_T pET15b_TEV linker Bastola, 2017 [2] 
TCB-530 Human V474A p97 pET15_T pET15b_TEV linker This study 
TCB-487 Human N660K p97 pET15_T pET15b_TEV linker This study 
TCB-496 Human T688A p97 pET15_T pET15b_TEV linker This study 
TCB-592 Human D649A/T688A p97 pET15_T pET15b_TEV linker This study 
Table S2. Primers used in this study. 
Name of primer Target of primer Sequence of primer 
PCR Primer 1 VCP-Cloning F 5’- CAG CGT TGT TCG CCC -3’ 
PCR Primer 2 VCP-Cloning R 5’- ACC CCC AGG GAA CAA G -3’ 
Sequencing Primer 1 VCP-Cloning F 5’- CAG CGT TGT TCG CCC -3’ 
Sequencing Primer 2 p97seq301F 5’- GCA TCC AGC CAT GCC CTG ATG TG -3’ 
Sequencing Primer 3 p97bp803F 5’- GAC CCT GAT TGC TCG AGC TG -3’ 
Sequencing Primer 4 p97 b1189F 5’- GAA CAG GTA GCC AAT GAG ACT -3’ 
Sequencing Primer 5 Hp97 1501-F 5’- GAC AAA TTC CTG AAG TTT GGC -3’ 
Sequencing Primer 6 p97seq1976F 5’- CTA ACC TGC GCA AGT CCC CAG TTG -3’ 
Table S3. HPLC conditions for NMS-873 intracellular concentration measurement. 
HPLC Shimadzu LC-20AD 
Column Type Hypersil Gold, 50x2.1 mm, 5 µm, Thermo Fisher 
Mobile Phases A: Water with 0.1% formic acid 
 B: Acetonitrile with 0.1% formic acid 
Pump Program Time (min) B (%) 
 0 30 
 0.02 30 
 0.8 95 
 1.8 95 
 1.9 30 
 3 30 
Flow Rate 400 µL/min 
Table S4. HPLC conditions for UPCDC-30245 intracellular concentration measurement. 
HPLC Shimadzu LC-20AD 
Column Type Atlantis T3, 50x4.6 mm, 5 µm, Waters 
Mobile Phases A: Water with 0.1% formic acid 
 B: Acetonitrile with 0.1% formic acid 
Pump Program Time (min) B (%) 
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 0 30 
 0.02 30 
 0.8 90 
 1.8 90 
 1.9 30 
 3 30 
Flow Rate 700 µL/min 
Table S5. Intracellular concentrations (μM per cell) of NMS-873 and UPCDC-30245 in A549 cells. 
 NMS-873 UPCDC-30245 
Treated time 
Treated Conc. 
3 h 6 h 3 h 6 h 
2.5 µM 
423.2 ±  
40.8 
468.1 ±  
13.5 
4970.0 ±  
353.0 
5079.8 ±  
284.6 
5 µM 
700.68 ±  
101.4 
825.4 ±  
79.0 
9481.0 ±  
599.8 
9900.2 ±  
428.0 
10 µM 
994.0 ±  
60.1 
1246.5 ±  
65.7 
4620.8 ±  
224.7 
3333.3 ±  
287.7 
Supplemental Methods 
Protein purification 
Plasmids used for generating WT and mutant p97 proteins can be found in the Supplemental Table S1; 
proteins were purified as previously described [1, 3]. 
ATPase activity 
To compare the ATPase activity of WT and mutant p97 proteins, each purified protein was diluted to a 
final monomer concentration of 25 nM in 50 μL ATPase assay buffer (50 mM Tris pH 7.4, 20 mM MgCl2, 
1mM EDTA, 0.5 mM TCEP, and 0.01% Triton X-100) containing 200 μM ATP. After 60 min incubation 
at room temperature, 50 μL Biomol Green reagent (Enzo Life Sciences) was added to stop the reaction 
and the absorbance at 635 nm was measured using a BioTek Synergy Neo plate reader. The eight-
dose titrations were performed by adding 30, 10, 3.3, 1.1, 0.37, 0.12, 0.04, and 0 μM compound to the 
reaction to determine the IC50 values of p97 inhibitors. The steady-state kinetic experiments were 
performed at 2 or 3 different concentrations of compound and 10 different ATP concentrations. The 
results were calculated from 6 replicates using GraphPad Prism 7.0. 
Cell viability 
Cell viability was measured using CellTiter Glo® Luminescent Cell Viability Assay (Promega) according 
to the manufacturer’s procedure. RMPI1640 or DMEM containing 5% FBS and 1% Penicillin-
Streptomycin (Thermo Fisher) was used as cell viability assay medium. To find the linear relationship 
between the relative luminescence unit and the number of viable cells, a standard curve for each cell 
line was generated. Generally, 30 μL of cell suspension was plated in 384-well white plates (Greiner) 
with serial 2 fold-dilutions (from 30000 to 284 cells per well). Twenty-four hours after seeding, 8 uL of 
assay media containing 5% DMSO was added into each well and plates were incubated for an 
additional 48 h at 37 °C in a 5% CO2 incubator. To test the anti-proliferative activity of p97 inhibitors, 
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cells were seeded at 750 to 3000 cells per well according to the linear range determined from the 
standard curve of each cell line. Twenty-four hours after seeding, cells were treated with the compounds 
(three-fold dilution, eight concentrations). After 48 hours of treatment, cell viability was measured using 
CellTiter Glo and IC50 values were calculated using the percentage of growth of treated cells versus the 
DMSO control. 
Western blot 
Parental or CB-5083 resistant human HCT116 cells were maintained in RPMI1640 medium containing 
5% FBS and 1% penicillin/streptomycin in 10 cm cell dishes. Cells were replated into 6-well plates (10^6 
cells/well) when they were 80% confluent. The next day inhibitors were added and cells were harvested 
after 6 hours of treatment. Cytoplasmic and nuclear fractions were isolated from the cell pellets with 
NE-PER Nuclear and Cytoplasmic Extraction Reagents (78835, Thermo Scientific). After determining 
protein concentration using Bradford reagent (Bio-Rad), 10 µg samples were loaded on a 4-20% Tris-
Glycine Mini-PROTEAN Gels (Bio-Rad). Proteins were transferred to nitrocellulose membranes using 
the Trans-Blot Turbo system (Bio-Rad). Primary antibodies used were K48 Ubiquitin (A101, Boston 
Biochem), p97 (MA3-004, Thermo Scientific), p62 (M162-3, MBL International Corporation), ATF4 (SC-
200, Santa Cruz Biotechnology), GAPDH (CST2118s, Cell Signaling Technology), CHOP (CST2895s, 
Cell Signaling Technology) and LC3 (PM036, MBL International Corporation). ECL reagent 
(WBKLS0500, MilliporeSigma) and ChemiDoc MP Imaging System (Bio-Rad) were used to image the 
blots. 
RNA extraction, molecular cloning and sequencing 
RNA extraction was performed using Direct-zol™ RNA MiniPrep Plus (Zymo Research Corporation, 
Cat. No. R2072) and TRIZOL LS REAGENT (Thermofisher, Cat. No. 10296028) according to the 
manufacturer’s protocol. One microgram of total RNA was reverse transcribed using Oligo(dT)20 
Primer (Thermofisher, Cat. No. 18418020) and ThermoScript Reverse Transcriptase (Thermofisher, 
Cat. No. 12236-014) according to the manufacturer’s protocol. cDNA sequence of p97 was amplified 
using Platinum SuperFi PCR Master Mix (Thermofisher, Cat. No. 12358-010). PCR product was purified 
after electrophoresis through 0.8% Agarose and extracted using QIAquick Gel Extraction kit (QIAGEN, 
Cat. No. 28115). Molecular cloning was performed using NEB PCR Cloning Kit (Biolabs, NEB #E1202) 
according to the manufacturer’s protocol. After overnight incubation, 5 clones were picked up and 
plasmids were purified using Plasmid miniprep kit (Bioland, Cat. No. PD01-01). Purified plasmids were 
sequenced by Sanger sequencing. PCR and sequencing primers refer to the Supplemental Table S2. 
Microscale Thermophoresis (MST) 
MST was carried out on a Monolith NT.115pico instrument (Nano-Temper Technologies) at 25 °C. Full-
length wild type p97 or p97 mutants were exchanged to 1x assay Buffer (50 mM Tris pH 7.4, 20 mM 
MgCl2, 1 mM EDTA, 0.5 mM TCEP, and 0.05% Tween 20). p97 was titrated against 25 nM of BODIPY™ 
FL ATP-γ-S (Thermofisher) in two-fold steps from 6.25 μM to 191 pM, with or without 1 μM of CB-5083. 
Assays were performed in hydrophilic capillaries in three independent experiments. 
Protein structure modeling 
Protein structure viewing and modeling were performed with Discovery Studio 4.0. The Build Mutants 
protocol was used to generate the mutant structures based on the wild type p97 structure (PDB 5FTJ). 
LC-MS/MS standard curves preparation 
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20,000 A549 cells per well in 90 μL of DMEM with 2.5% FBS and 1% Penicillin/Streptomycin were 
plated in a 96 well plate. After 24 hours, medium was removed, and cells were washed twice with ice-
cold DPBS. 90 μL of ACN was added to each well and shaken for 60 min at 800 rpm at room 
temperature. 10 μL of 10x compound (in 10% DMSO mixed with 90% ACN) was added to yield 
calibration curve samples with 1% DMSO in 100 μL ACN. The plate was centrifuged at 4000 rpm for 
15 min at 23°C, and 75 μL of supernatant was transferred to a fresh plate; the plate can be sealed and 
stored at -80°C. The concentrations for the standard curve are 0, 2.1, 6.2, 18.5, 55.6, 166.7, 500, and 
1500 nM. The standard curves are showed as Fig. S6. 
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